Previous 10 | Next 10 |
10x Genomics, Inc. (TXG) Q4 2021 Earnings Conference Call February 16, 2022, 04:30 PM ET Company Participants Eric Jaschke - Director of IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Conference Call Participants Tycho Peterson - JPMorgan Derik De Bruin - Ban...
Gainers: Marin Software Incorporated MRIN +34%. Global-E Online GLBE +17%. KnowBe4 KNBE +11%. ACV Auctions ACVA +7%. Outset Medical OM +5%. Losers: 10x Genomics TXG -23%. Applovin Corporation APP -20%. Brightcove BCOV -...
10x Genomics (TXG -0.3%) is trading ~18% lower in the post-market on Wednesday after the company set its 2022 revenue guidance below Wall Street forecasts despite a strong revenue beat for Q4 2021. Quarterly revenue jumped ~28% YoY to $143.5M after a rise in consumables revenue than...
10x Genomics press release (NASDAQ:TXG): Q4 GAAP EPS of -$0.16 misses by $0.08. Revenue of $490.5M (+241.8% Y/Y) beats by $342M. Shares -17%. 10x Genomics expects full year 2022 revenue to be in the range of $600 million to $630 million ($678.86M consensus), representing 22% to 28% growth ove...
10x Genomics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Outlook for 2022 FY 2021 revenue growth of 64% and Q4 2021 revenue growth of 28% over the corresponding periods of 2020 PR Newswire PLEASANTON, Calif. , Feb. 16, 2022 /PRNew...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Despite U.S. inflation, America’s economy is still the best house on the worst block. According to the latest data points, consumer prices surged more than 7% in January, the highest gain since February 1982 , per a...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We were opportunistic in the face of recent market volati...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We took advantage of market volatility in the fourth quar...
COVID-19 has dominated the healthcare space for a couple of years now. Indeed, it's been the dominant concern for most of the world. It has also produced some exciting investing opportunities. But there are outstanding opportunities outside of COVID, too. Three Fool.com contributors have fo...
10x Genomics to Report Fourth Quarter and Full Year 2021 Financial Results on February 16, 2022 PR Newswire PLEASANTON, Calif. , Jan. 26, 2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...